within Pharmacolibrary.Drugs.ATC.M;

model M04AA51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 126 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Allopurinol in combination with other agents is used primarily to treat gout and hyperuricemia by reducing uric acid production. It acts as a xanthine oxidase inhibitor. Some combinations may also contain agents that facilitate uric acid excretion or mitigate adverse effects. Allopurinol and its combinations are approved and commonly used in clinical practice.</p><h4>Pharmacokinetics</h4><p>PK parameters estimated for typical adult population, oral administration. No specific individual, sex, age, or co-morbidity differentiation. Parameters are estimates based on known single agent allopurinol models, as no published PK model exists for combinations.</p><h4>References</h4><ol><li><p>Toksvang, LN, et al., &amp; Schmiegelow, K (2022). Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations. <i>Leukemia</i> 36(7) 1749–1758. DOI:<a href=&quot;https://doi.org/10.1038/s41375-022-01591-4&quot;>10.1038/s41375-022-01591-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35654820/&quot;>https://pubmed.ncbi.nlm.nih.gov/35654820</a></p></li><li><p>Kankam, M, et al., &amp; Nguyen, M (2018). Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. <i>Journal of clinical pharmacology</i> 58(9) 1214–1222. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1119&quot;>10.1002/jcph.1119</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29733447/&quot;>https://pubmed.ncbi.nlm.nih.gov/29733447</a></p></li><li><p>Fernando, SL (2014). Drug-reaction eosinophilia and systemic symptoms and drug-induced hypersensitivity syndrome. <i>The Australasian journal of dermatology</i> 55(1) 15–23. DOI:<a href=&quot;https://doi.org/10.1111/ajd.12085&quot;>10.1111/ajd.12085</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23866082/&quot;>https://pubmed.ncbi.nlm.nih.gov/23866082</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M04AA51;
